General Manager

Description

• Setting the strategic direction for the Indonesian affiliate and leading your team to meet and exceed P&L targets through mid-to-long term strategic plans
• Building and maintaining strong, trusting relationships with key medical, payer, and government agencies, to ensure market access for our innovative portfolio
• Shaping and executing organizational strategy while developing people capabilities that are fit for the future
• Supervising negotiations for pricing and reimbursement across all products, ensuring our innovations reach the patients who need them
• Representing Novo Nordisk to local authorities and key opinion leaders across all therapeutic areas
• Identifying market trends and potential business challenges, preparing effective plans to address them proactively
• Driving a performance culture and winning mindset through empowering leadership and meaningful performance dialogues
• Ensuring all activities comply with Novo Nordisk internal policies, local regulations, and the highest ethical standards

Qualifications

• A relevant graduate-level degree (e.g., Pharmacy, Science, or Business Administration) with at least 10 years' experience in the pharmaceutical industry
• A minimum of 8 years of management experience leading functions such as sales, marketing, business development, or finance with proven success in multiple settings (affiliate/region/HQ) within Obesity/ Diabetes or other chronic therapy areas
• Previous experience in General Managerial roles managing similar level of complexities would be an advantage.
• At least 8 years in a people management position, leading and developing high-performing, cross-functional teams, preferably managing leaders
• Strong public affairs understanding, as interactions with external stakeholders are of high importance to this role
• Bold and ambitious leadership with a 'can-do' attitude, coupled with innovation and strong cultural understanding
• The ability to lead, inspire, and engage through role modelling and impactful communication while prioritizing compliance and ethics